Brief: Algorae Pharmaceuticals Partners With Peter Maccallum Cancer Centre For Second AI-Driven Drug Synergy Screening Program
30/03/2026 02:41
March 30 (Reuters) - Algorae Pharmaceuticals Ltd 1AI.AX: CO PARTNERS WITH PETER MACCALLUM CANCER CENTRE FOR SECOND AI-DRIVEN DRUG SYNERGY SCREENING PROGRAM Further company coverage: 1AI.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Algorae Pharmaceuticals
See all newsBrief: Algorae Pharmaceuticals Executes License & Supply Agreement With Torrent Pharma
Brief: Algorae Pharmaceuticals And Zydus Enter Exclusive Commercial Agreement
Brief: Algorae Pharmaceuticals Raises A$3.9 Million At A$0.012 Per Share
Brief: Algorae Pharmaceuticals Says TGA Accepts Initial Registration Dossier For Evaluation
Brief: Algorae Pharmaceuticals Partners With Peter Maccallum Cancer Centre For Second AI-Driven Drug Synergy Screening Program